Added to YB: 2025-12-10
Pitch date: 2025-10-12
RNA [bullish]
Avidity Biosciences, Inc.
+42.29%
current return
Author Info
No bio for this author
Company Info
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
Market Cap
$10.8B
Pitch Price
$50.48
Price Target
357.14 (+397%)
Dividend
N/A
EV/EBITDA
-14.84
P/E
-17.12
EV/Sales
429.70
Sector
Biotechnology
Category
growth
Avidity Biosciences, Inc. - $RNA
RNA: Pre-commercial biotech targeting muscular dystrophies w/ 3 late-stage drugs. Del-desiran (DM1) phase 3 readout end-2026, launch 2027. Est. 8K patients by 2030 at $400K annually = $3.2B revenue. Peak 25K patients = $10B sales. Del-brax (FSHD) adds similar revenue. Risks: adverse effects, Dyne competition, execution, dilution.
Read full article (11 min)